Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting
Psoriasis Clinical Trials
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting
Dermatology Clinical Trials
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting
Pediatric Dermatology Clinical Trials
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting
Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Intermittent Reduced Calorie Diet (IRCD)
Eligibility
Inclusion Criteria:
- Mild to moderate Crohn's disease (CDAI score 151-450)
- Between the ages of 18-70 (inclusive)
Exclusion Criteria:
- Women who are pregnant, nursing or expect to be pregnant
- Individuals allergic to nuts
- Individuals with a body mass index (BMI) lower than 18
- Individuals diagnosed with a serious medical condition (unless approved in writing by
a physician)
- Individuals who have been severely weakened by a disease or medical procedure
- Individuals who are taking medication which may not be safely consumed with a calorie
restricted diet
- Individuals with diabetes who are taking anti-diabetic drugs associated with risk of
hypoglycemia
- Individuals with more than mild-moderate cardiovascular disease or life-threatening
cancer (as determined by patient's physician) unless approved by a physician
- Individuals with history of severe cardiac disease (particularly uncompensated
congestive heart failure NYHA grade 2 or more or LVEF < 40%)
- Individuals with a history of syncope
- Individuals with dietary needs incompatible with the IRCD meal plan
- Individuals with liver or kidney disorders that may be affected by very low glucose
and protein content of the diet
- Patients on a calorie restricted diet will also be excluded
- Patients with relevant prior gastrointestinal surgery and consequences such as short
bowel syndrome, ostomy of small or large intestine,total colectomy, proctocolectomy,
ileoanal pouch will be excluded (not excluded are patients with resection of terminal
ileum, resection of short strictures of the small intestine, hemicolectomy).
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Touran Fardeen
Not Recruiting